Work

Aggressive Macroprolactinoma Refractory to Multiple Lines of Localized and Systemic Therapy

Year: 2025

Type: article

Abstract: Aggressive prolactinomas are rare and pose considerable therapeutic challenges, especially in cases refractory to conventional treatments, including dopamine agonists, surgery, and radiotherapy. We present a case of a 77-year-old man with refractory, treatment-resistant macroprolactinoma and describe the sequential use of capecitabine temozolomide, olaparib bevacizumab, pembrolizumab, and pazopanib. Despite disease progression on multiple lines of therapy, pazopanib achieved disease stability, after which the tumor demonstrated slow progression. This case highlights the urgent need for novel therapeutic approaches and predictive biomarkers in managing refractory aggressive prolactinomas.

Source: JCEM Case Reports

DOI: 10.1210/jcemcr/luaf216

Authors: Navya Konindala, Ravi Paluri, Hima Darapu

Institutions: Atrium Health Wake Forest Baptist, Wake Forest Baptist Comprehensive Cancer Center

Language: English

Topic: Pituitary Gland Disorders and Treatments

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $930